Analysts Set IQVIA Holdings Inc. (NYSE:IQV) PT at $267.00

Shares of IQVIA Holdings Inc. (NYSE:IQV) have received a consensus recommendation of “Moderate Buy” from the seventeen analysts that are covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $267.00.

Several research firms have issued reports on IQV. Evercore ISI boosted their price target on IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. Argus raised shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. The Goldman Sachs Group began coverage on shares of IQVIA in a report on Thursday, June 6th. They set a “buy” rating and a $270.00 price target on the stock. Truist Financial increased their price objective on shares of IQVIA from $292.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Finally, Robert W. Baird lifted their target price on shares of IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a research note on Friday, September 20th.

IQVIA Price Performance

NYSE IQV opened at $234.79 on Monday. The company has a 50-day moving average price of $241.49 and a 200-day moving average price of $233.19. IQVIA has a 52 week low of $167.42 and a 52 week high of $261.73. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The firm has a market capitalization of $42.80 billion, a P/E ratio of 32.08, a PEG ratio of 2.25 and a beta of 1.49.

IQVIA (NYSE:IQV) last announced its earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. During the same period in the prior year, the company earned $2.22 earnings per share. The firm’s revenue was up 2.3% on a year-over-year basis. Equities research analysts anticipate that IQVIA will post 10.25 earnings per share for the current year.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is currently owned by company insiders.

Institutional Trading of IQVIA

Several hedge funds have recently made changes to their positions in the business. Canada Pension Plan Investment Board raised its position in IQVIA by 6.6% during the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after purchasing an additional 211,653 shares during the period. Lazard Asset Management LLC raised its holdings in IQVIA by 0.9% during the 1st quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock valued at $825,416,000 after buying an additional 30,014 shares during the period. Farallon Capital Management LLC lifted its position in IQVIA by 3.1% in the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock worth $618,046,000 after buying an additional 86,870 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in IQVIA by 3.8% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock worth $634,927,000 after buying an additional 92,293 shares during the period. Finally, Capital Research Global Investors raised its stake in shares of IQVIA by 7.2% in the first quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock valued at $540,882,000 after acquiring an additional 143,533 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.